Baiyun Mountain (600332): Steady growth in 24Q1 performance promotes high-quality development
Baiyun Mountain (600332): 1Q24 results are in line with expectations, the cost rate declined year-on-year
Baiyunshan (600332) Annual Report Review: Steady Performance Growth, Continued Focus on Improving Marketing Management Efficiency
Baiyun Mountain (600332): The deduction of non-net profit is in line with expectations, and the big health sector accelerates overseas deployment
Research Report Nuggets丨Tianfeng Securities: Baiyunshan's performance has grown steadily in 23 years, and all major sectors have gone hand in hand to maintain a “buy” rating
Baiyun Mountain (600332): Steady growth in performance, major sectors go hand in hand
Baiyun Mountain (600332): The strategic layout of the subsidiary to be listed on the New Third Board is progressing steadily
Bank Ratings|Daimo: Lowering Baiyun Mountain's target price to HK$24.5 “in sync with the market”
Analysts Are Bullish on These Healthcare Stocks: Guangzhou Baiyunshan Pharmaceutical Holdings Company (GZPHF), Mesoblast Limited (MEOBF)
Baiyunshan (600332): Performance was in line with expectations, and gross margin for the third quarter increased year-on-year
DaXing Rating|Damo: Lowering Baiyunshan's target price to HK$26 to maintain the “in sync with the market” rating
Baiyun Mountain (600332): Consolidate the steady and far-reaching development of the main business and look forward to continued deepening of reforms
Baiyun Mountain (600332): Performance growth is in line with expectations and closely follows the “double effect improvement” theme
Baiyun Mountain (600332): Performance is in line with expectations, and the proprietary Chinese medicine business is growing brilliantly
Baiyun Mountain (600332): Performance meets expectations, main business maintains a steady trend
Baiyunshan (600332): Performance meets expectations and actively lays out the medical sector
Baiyunshan (600332): Performance meets expectations and actively builds a series of Ji products
Baiyun Mountain (600332): The recovery of the epidemic and hot summer will drive herbal tea sales to resume traditional Chinese medicine support policies to promote Dannan Medicine
Baiyun Mountain (600332): Profits meet expectations and actively explore professional manager mechanisms
Baiyunshan (600332): Net profit increased 27% year-on-year in 2021, and both the Dannan Pharmaceutical and Health sectors recovered in line with expectations
No Data